What's on this Page
Non FDG PET radiotracers in the oncological setting
What other non FDG PET radiotracers are available for use in the oncological setting?
Noninvasive PET assessment of other molecular characteristics of tumors may be useful to characterize tumor biology and to optimize patient management. For example, pretreatment detection of hypoxia in lung cancer and other tumors is useful, as tumor hypoxia generally decreases tumor responsiveness to radiotherapy and chemotherapy. Similarly, pretreatment detection of estrogen receptor expression in metastatic breast cancer is useful, because such tumors will then generally respond to antiestrogen systemic therapies.
Here is the table for a short list of some other non-FDG radiotracers that are available to assess patients with cancer.
Some Non FDG Radiotracers Available for Oncological PET Imaging
| TARGET | REPRESENTATIVE RADIOTRACER |
|---|---|
| Amino acid metabolism | L-[methyl- 11 C]methionine ( 11 C-MET) |
| 18 F-4-fluoroglutamine | |
| 18 F-6-fluorodihydroxyphenylalanine ( 18 F-FDOPA) | |
| Cell proliferation | 3′-deoxy-3′- 18 F-fluorothymidine ( 18 F-FLT) |
| Phospholipid metabolism | 11 C-choline |
| 18 F-fluorocholine ( 18 F-FCH) | |
| Angiogenesis | 18 F-galacto-arginine-glycine-aspartate ( 18 F-RGD) |
| Hypoxia | 18 F-2-(2-nitro- 1 H-imidazol-1-yl)- N -(2,2,3,3,3-pentafluoropropyl)-acetamide ( 18 F-EF5) |
| 18 F-fluoromisonidazole ( 18 F-FMISO) | |
| 64 Cu-(II)-diacetyl-bis(N4-methylthiosemicarbazone) ( 64 Cu-ATSM) | |
| Apoptosis | 4- 18 F-fluorobenzoyl-annexin V |
| Bone metabolism | 18 F-sodium fluoride ( 18 F-NaF) |
| Receptor Expression | |
| Somatostatin | 68 Ga-DOTA-Phe 1 -Tyr 3 -octreotide ( 68 Ga-DOTA-TOC) |
| 68 Ga-DOTA-1-NaI 3 -octreotide ( 68 Ga-DOTA-NOC) | |
| 68 Ga-DOTA-Tyr 3 -Thr 8 -octreotide ( 68 Ga-DOTA-TATE) | |
| Estrogen | 16α- 18 F-fluoroestradiol-17β ( 18 F-FES) |
